Skip to content
lifestyle.serversfree.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
FibroBiologics, Inc.
FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers
June 3, 2026
FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting
May 24, 2026
FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics
May 22, 2026
FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus
May 21, 2026
FibroBiologics CEO Issues Letter to Shareholders
May 20, 2026
FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring
May 20, 2026
FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
May 18, 2026
FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update
May 18, 2026
FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026
May 18, 2026
FibroBiologics Compliant with All Nasdaq Listing Requirements
May 16, 2026
1
2
3
Next Page
→